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Bone histomorphometryVitamin D insufﬁciency is common in elderly people worldwide, and intake of supplementary calcium and
vitamin D is recommended to those with a high risk of fracture. Several clinical studies and meta-analyses
have shown that calcium and vitamin D supplementation reduces osteoporotic fractures, and a strong correlation
exists between vitamin D status and fracture risk. Vitamin D supplementations improve calcium balance in the
body; however, it remains unclear whether vitamin D directly affects bone metabolism. Recently, eldecalcitol
(ELD), an active form of vitamin D analog, has been approved for the treatment of osteoporosis in Japan. A
3-year clinical trial showed ELD treatment increased lumbar spine bonemineral density (BMD) and reduced frac-
ture risk in patients with osteoporosis. To evaluate the mechanism of ELD action in bone remodeling, ovariecto-
mized cynomolgus monkeys were treated with 0.1 or 0.3 μg/day of ELD for 6 months. This treatment increased
lumbar BMD by 4.4% and 10.2%, respectively, and suppressed ovariectomy-induced increases in bone turnover
markers compared to OVX-vehicle control. Histomorphometric analysis of bone revealed that both bone forma-
tion parameters and bone resorption parameters in the trabecular bone of the lumbar vertebrae were suppressed
by ELD treatment. ELD treatment also improved biomechanical properties of the lumbar vertebrae and the fem-
oral neck in the ovariectomized cynomolgus monkeys. These results indicate that, in a bone-remodeling animal
model, ELD increases BMD and improves bone biomechanical properties by normalizing bone turnover. There-
fore, ELD has a direct and potentially beneﬁcial effect on bone metabolism.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Eldecalcitol [1α,25-dihydroxy-2β-(3-hydroxypropyloxy)vitamin D3;
ELD], an analog of calcitriol [1α,25-dihydroxyvitamin D3; 1,25(OH)2D3],
has been demonstrated to increase bone mass, to suppress bone turn-
over markers, and to enhance bone strength in rodents [1,2]. ELD sup-
presses RANKL expression in osteoblasts [3], suppresses differentiation
of preosteoclasts to mature osteoclasts [4], and therefore, reduces the
number of mature osteoclasts on the bone surface. The binding afﬁnity
of ELD to the vitamin D receptor (VDR) is approximately half the binding
afﬁnity of 1,25(OH)2D3, but its binding afﬁnity to serum vitamin
D-binding protein (DBP) is 4 times that of 1,25(OH)2D3 [5]. Also, ELD
is resistant to enzymatic degradation by CYP24A1, a major vitamin D., 2-1-1Nihonbashi-Muromachi,
to).
Inc. Open access under CC BY-NC-NDmetabolic enzyme in the cell, despite ELD strongly inducing CYP24A1
in the intestine and kidney in vivo [6,7]. These characteristics may ac-
count for its long half-life in the circulation in vivo [8]. A randomized,
double-blind, placebo-controlled clinical trial in osteoporotic patients re-
ceiving cholecalciferol (vitamin D3) supplementation demonstrated that
treatment with 0.5 to 1.0 μg/day ELD for 12 months increased lumbar
spine and hip bonemineral density (BMD) and decreased bone turnover
markers compared to placebo in a dose-dependent manner without
causing sustained hypercalcemia or hypercalciuria [9]. A randomized,
double-blind, active-comparator, clinical trial of ELD in postmenopausal
women with osteoporosis demonstrated that ELD signiﬁcantly de-
creased the incidence of vertebral fractures and wrist fractures in com-
parison to alfacalcidol, 1α-hydroxyvitamin D3, in 3 years [10]. On the
basis of these results, eldecalcitol was approved for the treatment of
osteoporosis in Japan.
Female nonhuman primates have a very similar reproductive phys-
iology and skeletal anatomy to those of women, with intracortical bone
remodeling (unlike in rodent models) and exhibiting an increase in
bone turnover and bone loss following ovariectomy [11–13]. However,
it is well known that NewWorld primates are resistant to vitaminD due
to the existence of intracellular vitamin D-binding protein, while Old license.
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be sensitive to the effects of vitamin D similar to humans [14]. Recent
investigations of primate bone metabolism have examined rhesus,
cynomolgus and pigtailed macaques, baboons, and African green mon-
keys, all of which are Old World primates. Among those, cynomol-
gus monkeys are the most commonly used for evaluation of anti-
osteoporotic agents, especially for the evaluation of nonclinical efﬁcacy,
pharmacology, and safety in bone [15–17]. Although the regulation of
calcium homeostasis and circulating levels of vitamin D metabolites in
this primate are quite different from those in humans, we believe that
the ovariectomized cynomolgus monkey is a suitable animal model to
test the effect of eldecalcitol on bone metabolism.
In this study, we evaluated the effect of ELD on BMD, bone turn-
over, bone histology/histomorphometry, and bone strength in ovari-
ectomized nonhuman primates.
Materials and methods
Animals and experimental design
All animal procedures were approved by Charles River Montreal
Animal Care Committee and were performed in an Association for
Assessment and Accreditation of Laboratory Animal Care-accredited
facility. The study was performed under Good Laboratory Practice
conditions according to the protocol, and was consistent with Stan-
dard Operating Procedures established at Charles River Laboratories,
Quebec, Canada. Data are presented from 2 separate experiments;
each experiment reports a single dose level of eldecalcitol (0.1 or
0.3 μg/kg) and its corresponding OVX-vehicle control group data.
Unless stated otherwise, all the procedures described below were
the same for both experiments.
Our study used female cynomolgus monkeys, at least 9 years of
age from China. Animals were housed in pairs, and were fed Certiﬁed
Hi-Fiber Primate Diet 5 K91 (PMI Nutrition International Inc., St.
Louis, MO, USA) or 2050C Teklad Certiﬁed Global 20% Protein Primate
Diet (Harlan Laboratories, Indianapolis, IN, USA) twice daily, with
food supplements of Prima-Treats (Bio Serv, Frenchtown, NJ, USA)
and/or fresh fruit, and had free access to water. The animal room
environment was controlled, with settings targeted at a temperature
of 22 ± 3 °C, humidity of 50 ± 20%, 12 h light and 12 h dark photo-
period, and 12 air changes per hour.
Animals were acclimated for a period of approximately 5 to
6 weeks after receipt prior to the baseline monitoring period. Only
animals considered in good health, with established menses, minimal
skeletal abnormalities, closed epiphyseal plates, and normal baseline
serum/urine chemistry panels were included (data not presented).
A total of 40 animals were used in the study. For each experiment,
20 animals were randomly assigned to either the OVX-vehicle control
group or the eldecalcitol group. Following completion of baseline
bone mineral density (BMD) measurements by dual-energy X-ray ab-
sorptiometry (DXA), groups were balanced to ensure that age, body
weight, whole body bone mineral content (BMC), and lumbar spine
BMD were equivalent across groups within each experiment.
The surgical procedures were performed under general anesthesia
which included an injection of glycopyrrolate, ketamine hydrochloride,
and xylazine, followed by isoﬂurane gas. Daily oral gavage treatment
commenced the day following ovariectomy, with either OVX-vehicle
control (OVX-Veh1 or OVX-Veh2) or eldecalcitol (at 0.1 μg/kg in the
ﬁrst experiment or 0.3 μg/kg in the second experiment), and continued
for 6 months. Body weights were monitored weekly and food con-
sumption assessed twice daily (data not presented).
Clinical chemistry and hormone analyses
Animals were fasted overnight prior to sample collection. Blood
samples were collected prior to surgery and prior to termination after6 months of treatment. For the second experiment, samples were also
collected at month 3. After serum separation, serum calcium and phos-
phorus were analyzed with a Roche Hitachi 717 Chemistry Analyzer
(Hitachi High-Tech Corp., Tokyo, Japan). The serum bone-speciﬁc alka-
line phosphatase (BAP) was measured with a Metra BAP ELISA kit
(Quidel Corporation, San Diego, CA, USA) or Tandem-R-Ostase IRMA
assay kit (Hybritech Inc., San Diego, CA, USA), and the serum collagen
C-telopeptide (CTX) was measured with a CrossLaps ELISA kit (Nordic
Bioscience Diagnostics, Herlev, Denmark). At the same time points
parathyroid hormone (PTH) was measured with a Coat-A-Count Intact
PTH IRMA kit (Diagnostic Products Corporation, Los Angeles, CA,
USA), and vitamin D metabolites were measured with a Gamma 1,25
dihydroxyvitamin D RIA kit (Immunodiagnostic Systems Inc., Scottsdale,
AZ, USA) and a 25-hydroxyvitamin D RIA kit (Diasorin S.p.A., Saluggia
[Vercelli], Italy).
Bone densitometry by DXA and peripheral quantitative computed
tomography (pQCT)
Areal BMD (aBMD) of the lumbar spine (L1–L4) and right proximal
femur (total hip) were measured by DXA (QDR 2000 plus; Hologic Inc.,
Bedford, MA, USA) at baseline and at month 6 (experiment 1) or at
months 3 and 6 (experiment 2). The coefﬁcient of variation of DXA
scanning with repositioning ranged from 0.8% for lumbar spine aBMD
to 4.5% for femoral neck aBMD.
pQCT (XCT Research SA+; StratecMedizintechnik GmbH, Germany)
was used to measure volumetric bone mineral content (vBMC) and vol-
umetric BMD (vBMD) at metaphyseal and diaphyseal sites of the right
tibia at baseline and at month 6 (experiment 1) or at months 3 and 6
(experiment 2). Metaphyseal data were generated as an average from
3 scans separated by 0.5 mm at the tibia/ﬁbula junction (contour
mode 2: threshold 0.446 cm−1; peelmode 2: threshold 0.550 cm−1).
A diaphyseal scan was taken at approximately 12% of the bone length
(peelmode 2, cortmode 2: threshold 0.930 cm−1) toward the center of
the tibia from the metaphyseal scans. Nominal voxel size was 0.35 mm.
The coefﬁcient of variation of pQCT scanning with repositioning
was 0.2% to 1.1% at the proximal tibia across all variables obtained
at metaphyseal and diaphyseal sites.
Bone histomorphometry
L2 vertebrae and right proximal femurs were collected for bone
histomorphometric analysis. Each animal was injected with 8 mg/kg
of calcein subcutaneously, 15 days and 5 days prior to termination.
All bone samples were ﬁxed in 10% neutral-buffered formalin for
3 days and transferred to 70% ethanol. Bones were then trimmed,
dehydrated, and embedded in methyl methacrylate. Trabecular bone
sections were prepared in the frontal plane for the femur neck, and in
the sagittal plane for the L2 vertebral body. Dynamic histomorphometry
was performed on 7 μm-thick unstained sections, while 5 μm-thick
sections were stained with Goldner's trichrome for static parameters
and with toluidine blue for wall thickness (W.Th). Cortical bone his-
tomorphometry was performed on 2 unstained transverse sections at
the femur diaphysis, ground to 20–40 μm in thickness. Measurements
were collectedwith a Bioquant image analyzer (Bioquant Image Analysis
Corporation, Nashville, TN, USA) linked with an Olympus BX-60 micro-
scope (Olympus Corporation, Tokyo, Japan) equipped with bright and
epiﬂuorescence illumination Static and dynamic parameters were
measured and reported as outlined by the ASBMR histomorphometry
nomenclature committee [18].
Bone strength
Bone biomechanical testing was performed with an MTS 858 Mini
Bionix servohydraulic test system (TestResources Inc., Shakopee, MN,
USA), and data was collected using Testworks (v3.8A) for Teststar II
Table 1
Serum chemistry and calcium-regulating hormones after eldecalcitol treatment.
OVX-Veh1 ELD 0.1 μg/kg OVX-Veh2 ELD 0.3 μg/kg
Serum calcium (mg/dL) 10.6 ± 0.5 10.8 ± 0.7 10.2 ± 0.4 12.5 ± 1.1⁎
Serum phosphorus (mg/dL) 6.2 ± 0.6 4.9 ± 0.7⁎ 6.2 ± 0.8 5.9 ± 0.9
Parathyroid hormone (pg/mL) 64.9 ± 40.5 82.8 ± 94.5 50.2 ± 20.6 4.2 ± 0.9⁎
1α,25-dihydroxyvitamin D (pmol/L) 342.6 ± 145.7 22.6 ± 10.9⁎ 368.8 ± 146.5 26.2 ± 8.7⁎
25-hydroxyvitamin D (ng/mL) 97.2 ± 28.7 80.4 ± 21.1 143.8 ± 26.2 59.9 ± 26.2⁎
Data are presented as mean ± SD.
⁎ p ≤ 0.05 vs. OVX-vehicle control.
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gauze and plastic wrap and stored frozen at−20 °C until testing. Verte-
bral bodies and vertebral core specimens were tested to failure in axial
compression. Left femurs were used for the 3-point bending and the
femoral neck shear tests. Left tibias (the ﬁrst experiment) or right
humerus (the second experiment) were used to prepare cortical beam
specimens for the 3-point bending test.
Vertebral end-plates and spinous processes of the L3 and L5 vertebrae
were removed with a diamond band saw to obtain a specimen with
plano-parallel ends. Two vertebral trabecular cores (cranial and caudal)
were prepared from L5 using a drill press. pQCT was used to determine
vBMC and vBMD of L3 vertebral bodies and L5 vertebral cores prior to
biomechanical testing. The cortical cross-sectional moment of inertia
(CSMI) in the plane of the 3-point bending test at the femoral diaphysisA
B
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Fig. 1. Percentage change from baseline values in (A) activity of serum bone-speciﬁc
alkaline phosphatase and (B) concentration of serum collagen C-telopeptide. Symbols
indicate the groups as follows: OVX-Veh1, open squares (□); eldecalcitol 0.1 μg/kg,
closed squares (■); OVX-Veh2, open circles (○); eldecalcitol 0.3 μg/kg, closed circles (●).
Data are presented as mean ± standard error. #: p ≤ 0.05 vs. OVX-Veh1; *: p ≤ 0.05 vs.
OVX-Veh2.was determined by pQCT. In order to prepare cortical beams, a strip of
bone with dimensions approximately 1 × 3 × 35 mm was milled from
the diaphysis of the left tibia or right humerus.
Peak load was recorded as the maximum of the load–displacement
curve, and stiffness was the slope of the linear portion. Work to failure
was calculated as the area under the curve to the breaking point for
3-point bending and shear tests, and to peak load for compression tests.
Yield loads for the whole vertebrae and vertebral cores were calculated
from the elastic regionof the load–displacement curve. Ultimate strength,
elasticmodulus, and toughnesswere calculated from the 3-point bending
test results using the CSMI.
Statistics
Statistical analyses were performed using SAS (v8.1) (SAS Institute,
Cary, NC, USA) for each experiment separately. In vivo densitometryA
B
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Fig. 2. Percentage change from baseline values in (A) lumbar spine (L1–L4) areal BMD
and (B) areal BMD of proximal femur as measured by DXA. Symbols indicate the groups
as follows: OVX-Veh1, open squares (□); eldecalcitol 0.1 μg/kg, closed squares (■);
OVX-Veh2, open circles (○); eldecalcitol 0.3 μg/kg, closed circles (●). Data are presented
as mean ± standard error. #: p ≤ 0.05 vs. OVX-Veh1; *: p ≤ 0.05 vs. OVX-Veh2.
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dose values prior to analysis. If group variances were homogenous
based on a Levene's test, groupmeanswere compared using a paramet-
ric one-way analysis of variance (ANOVA). If a signiﬁcant group effect
was found, then pairwise comparisons were made to compare the
OVX-vehicle control with the corresponding eldecalcitol-treated group.
If group variances were found to be heterogeneous, data were log-
transformed and reanalyzed. If heterogeneous variances remained, a
heteroscedastic ANOVA model was employed.Results
Blood, urine chemistry and hormones
At month 6, animals treated with 0.3 μg/kg of eldecalcitol devel-
oped slight hypercalcemia, and serum phosphorus levels were slightly
decreased at 0.1 μg/kg eldecalcitol (Table 1). Eldecalcitol at 0.3 μg/kg sig-
niﬁcantly decreased PTH, 1,25(OH)2D3, and 25(OH)D relative to control
(OVX-Veh2); however, only 1,25(OH)2D3was signiﬁcantly decreased by
0.1 μg/kg treatment in comparison to the control (OVX-Veh1).Biochemical markers of bone turnover
Biochemical markers of bone turnover gradually increased after
ovariectomy in the OVX-vehicle control groups (Fig. 1). Treatment
with 0.1 or 0.3 μg/kg of eldecalcitol prevented the ovariectomy-induced
increases in the bone formation marker BAP (Fig. 1A) and in the bone
resorptionmarker CTX (Fig. 1B). Thus, these results indicated that treat-
ment with eldecalcitol suppressed the increased bone turnover caused
by ovariectomy in nonhuman primates.A
B
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Fig. 3. Percentage change in volumetric bone mineral content (BMC) and volumetric bone
peripheral QCT. Symbols indicate the groups as follows: OVX-Veh1, open squares (□); eldeca
closed circles (●). Data are presented as mean ± standard error. #: p ≤ 0.05 vs. OVX-Veh1Bone densitometry
Ovariectomy induced only slight decreases in lumbar spine aBMD at
6 months post-surgery (−3.3% from baseline for OVX-Veh1 and−0.6%
for OVX-Veh2; Fig. 2A) with no meaningful change in the proximal
femur (hip) aBMD (Fig. 2B) as measured by DXA. These small aBMD
responses to ovariectomy in nonhuman primates were consistent with
results of previous studies [13,14]. Compared to their corresponding
OVX-vehicle controls, treatment with eldecalcitol for 6 months resulted
in statistically signiﬁcant increases in aBMD in the lumbar spine: 4.4% in-
crease relative to baseline at 0.1 μg/kg and 10.2% increase at 0.3 μg/kg,
and in the proximal femur: 10.8% increase at 0.3 μg/kg (Fig. 2).
At the proximal tibia metaphysis, treatment with eldecalcitol at
0.1 and 0.3 μg/kg for 6 months resulted in dose-related increases in
total vBMC of 3.2% and 11.4%, and vBMD of 3.1% and 12.6% from the
baseline, respectively (Fig. 3A). Statistically signiﬁcant differences
compared to the OVX-vehicle control were observed at month 3
and at month 6 for 0.3 μg/kg eldecalcitol (Fig. 3A).
At the tibia diaphysis site, treatment with 0.3 μg/kg of eldecalcitol
resulted in statistically signiﬁcant increases in cortical vBMC, compared
to OVX-vehicle control, with no signiﬁcant change in cortical vBMD
(Fig. 3B). Cortical vBMD decreased in control groups (OVX-Veh1 and
OVX-Veh2), whereas eldecalcitol treatment maintained cortical vBMD
in both the 0.1 and 0.3 μg/kg treatment groups (Fig. 3B).
Bone histomorphometry
Although we tried to create nearly homogeneous groups of female
monkeys for the 2 experiments, the average values of each bone his-
tomorphometric parameter were substantially different. Therefore, in
order to compare results from 2 experiments, we used the absolute
value as well as the percentage change in each parameter (Table 2).-6
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Cortical BMD
mineral density (BMD) of (A) tibia metaphysis and (B) tibia diaphysis as measured by
lcitol 0.1 μg/kg, closed squares (■); OVX-Veh2, open circles (○); eldecalcitol 0.3 μg/kg,
; *: p ≤ 0.05 vs. OVX-Veh2.
Table 2
Bone histomorphometry.
(A) Histomorphometric variables of lumbar vertebral trabecular bone
Group L2 trabecular bone
OVX-Veh1 ELD 0.1 μg/kg % change OVX-Veh2 ELD 0.3 μg/kg % change
BV/TV (%) 24.5 ± 1.0 26.7 ± 2.5 9 25.5 ± 2.4 29.2 ± 1.6 15
Tb.Th (μm) 105.0 ± 4.4 109.6 ± 7.7 5 104.8 ± 4.7 119.2 ± 4.6⁎ 14
Tb.N (/mm) 2.4 ± 0.1 2.4 ± 0.1 3 2.4 ± 0.1 2.5 ± 0.1 4
Tb.Sp (μm) 329.1 ± 22.5 311.4 ± 21.5 −5 321.0 ± 24.3 294.9 ± 20.0 −8
OV/BV (%) 2.7 ± 0.7 0.2 ± 0.1⁎ −92 4.8 ± 0.4 0.3 ± 0.2⁎ −94
O.Th (μm) 9.2 ± 0.4 4.6 ± 0.8⁎ −50 7.6 ± 0.3 4.5 ± 0.8⁎ −41
OS/BS (%) 24.1 ± 4.6 3.2 ± 1.1⁎ −87 45.5 ± 2.7 6.6 ± 1.7⁎ −86
Ob.S/BS (%) 19.6 ± 3.4 2.3 ± 0.8⁎ −88 42.4 ± 3.0 5.1 ± 1.4⁎ −88
Oc.S/BS (%) 0.9 ± 0.2 0.5 ± 0.1 −49 2.9 ± 0.3 0.7 ± 0.5⁎ −75
ES/BS (%) 4.7 ± 0.7 3.5 ± 0.8 −25 4.9 ± 0.8 1.3 ± 0.6⁎ −73
MS/BS (%) 16.1 ± 2.8 1.7 ± 0.9⁎ −89 23.2 ± 1.2 1.4 ± 0.6⁎ −94
sLS/BS (%) 11.2 ± 1.9 1.9 ± 0.9⁎ −83 18.6 ± 1.0 1.8 ± 0.8⁎ −90
dLS/BS (%) 10.5 ± 1.9 0.8 ± 0.5⁎ −92 13.9 ± 0.8 0.5 ± 0.2⁎ −97
MAR (μm/day) 1.1 ± 0.03 0.7 ± 0.2⁎ −37 1.1 ± 0.04 0.6 ± 0.2⁎ −47
BFR/BS (μm3/μm2/year) 63.3 ± 11.7 6.2 ± 3.2⁎ −90 91.0 ± 6.8 7.0 ± 4.0⁎ −92
BFR/BV (%/year) 120.4 ± 22.9 10.9 ± 4.9⁎ −91 175.1 ± 13.6 11.0 ± 6.2⁎ −94
Ac.f (/year) 3.5 ± 0.7 0.40 ± 0.2⁎ −88 5.5 ± 1.1 0.80 ± 0.4⁎ −85
(B) Histomorphometric variables of cortical bone
Group Femoral diaphysis
OVX-Veh1 ELD 0.1 μg/kg % change OVX-Veh2 ELD 0.3 μg/kg % change
Tt.T.Ar (mm2) 58.8 ± 3.4 55.9 ± 2.5 −5 51.2 ± 2.2 54.7 ± 1.5 8
Ct.Ar (mm2) 43.7 ± 2.1 41.8 ± 1.5 −4 36.6 ± 1.4 39.0 ± 1.2 7
Me.Ar (mm2) 15.1 ± 1.8 14.1 ± 1.4 −7 14.6 ± 1.7 15.7 ± 1.4 8
Ct.Wi (mm) 2.1 ± 0.1 2.1 ± 0.1 −1 1.9 ± 0.1 1.9 ± 0.1 0
%Po.Ar (%) 2.1 ± 0.2 1.8 ± 0.2 −16 2.3 ± 0.3 1.8 ± 0.5 −22
Ps.L.Pm/Ps.Pm (%) 16.5 ± 7.7 5.4 ± 1.8 −67 39.9 ± 7.9 30.9 ± 6.7 −23
Ps.MAR (μm/day) 0.8 ± 0.1 0.5 ± 0.1 −36 0.8 ± 0.1 1.1 ± 0.1 38
Ps.BFR/BS (μm3/μm2/year) 62.6 ± 29.7 12.2 ± 5.6 −80 133.0 ± 29.7 135.4 ± 31.8 2
Ec.L.Pm/Ec.Pm (%) 15.7 ± 8.7 10.4 ± 3.7 −33 42.2 ± 9.5 38.9 ± 12.3 −9
Ec.MAR (μm/day) 0.7 ± 0.1 0.6 ± 0.1 −3 0.8 ± 0.1 1.0 ± 0.3 25
Ec.BFR/BS (μm3/μm2/year) 56.0 ± 32.3 33.1 ± 15.2 −41 146.8 ± 41.0 250.7 ± 91.2 71
H.L.Pm/H.Pm (%) 10.7 ± 2.5 5.8 ± 1.4 −45 19.7 ± 4.9 5.1 ± 2.3⁎ −74
H.BFR/BS (μm3/μm2/year) 53.5 ± 13.4 28.0 ± 7.1 −48 85.9 ± 21.8 27.3 ± 14.2⁎ −68
H.MAR (μm/day) 1.4 ± 0.0 1.2 ± 0.1 −10 1.2 ± 0.2 0.8 ± 0.2 −42
H.Ac.f (/year) 10.5 ± 1.9 9.2 ± 2.4 −12 21.8 ± 4.4 11.9 ± 3.1 −45
Data are presented as mean ± SEM.
% change: Data are presented as percent difference from OVX-Vehicle control.
⁎ p ≤ 0.05 vs. OVX-Vehicle control.
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increased bone volume (BV/TV) and trabecular thickness (Tb.Th), and
decreased trabecular separation (Tb.Sp) in lumbar vertebral (L2) tra-
becular bone (Table 2A). All measured structural (OV/BV, O.Th, OS/BS
and Ob.S/BS) and dynamic variables of bone formation (MS/BS, sLS/
BS, dLS/BS, MAR, BFR/BS and BFR/BV) were signiﬁcantly suppressed
by the eldecalcitol treatment. Bone resorption parameters were also
diminished with eldecalcitol treatment as demonstrated by diminution
of Oc.S/BS and ES/BS that reached signiﬁcance at 0.3 μg/kg. Eldecalcitol
treatment also signiﬁcantly reduced bone remodeling activation, as
measured with activation frequency (Ac.f). These results indicated
that eldecalcitol signiﬁcantly suppressed bone remodeling in ovariecto-
mized nonhuman primates.
In cortical bone of the femoral diaphysis, there were no signiﬁcant
differences at either dose between the eldecalcitol-treated groups and
the corresponding OVX-vehicle control groups for the structural param-
eters of cortical area (Ct.Ar), medullary area (Me.Ar), and cortical thick-
ness (Ct.Wi) (Table 2B). However, inHaversian canals, haversian labeled
surfaced (H.L.Pm/Ec.Pm), mineral apposition rate (H.MAR) and bone
formation rate (H.BFR/BS) were dose-dependently decreased, and a
signiﬁcant change was observed in H.L.Pm/Ec.Pm and H.BFR/BS with
0.3 μg/kg eldecalcitol treatment. Activation frequency in Haversian
canals (H.Ac.f) of cortical bone was suppressed as was observed in
trabecular bone (Ac.f). The reduced Haversian remodeling was consis-
tent with the non-signiﬁcant reduction in cortical porosity noted witheldecalcitol treatment. At the periosteal and endocortical bone surfaces,
treatment with 0.1 μg/kg eldecalcitol tended to suppress periosteal
and endocortical label surfaces (Ps.L.Pm/Ec.Pm; Ec.L.Pm/Ec.Pm)mineral
apposition rates (Ps.MAR, Ec.MAR) andbone formation rates (Ps.BFR/BS,
Ec.BFR/BS). On the other hand, all of those parameters (Ps.MAR, Ec.MAR,
Ps.BFR/BS, Ec.BFR/BS) slightly increased with 0.3 μg/kg eldecalcitol
treatment. These results suggest treatment with 0.3 μg/kg eldecalcitol
stimulates periosteal and endocortical bone formation, while 0.1 μg/kg
eldecalcitol suppresses periosteal and endocortical bone formation.
Although, no signiﬁcant changes from OVX-vehicle control in these pa-
rameters were found in either treatment group, at least daily treatment
with either 0.1 or 0.3 μg/kg of eldecalcitol for 6 months did not overly
suppress periosteal and endocortical bone formation in ovariectomized
monkeys.
Bone strength
In whole lumbar vertebrae, eldecalcitol treatment improved all
bone strength parameters compared to OVX-vehicle controls. Statisti-
cal signiﬁcance was attained for peak load, apparent strength, yield
load, yield stress, stiffness, elastic modulus, and work to failure
with 0.3 μg/kg eldecalcitol treatment and for stiffness with 0.1 μg/kg
eldecalcitol treatment (Table 3A). Vertebral core compression revealed
signiﬁcant increases in yield load, yield stress, stiffness and elastic mod-
ulus with 0.3 μg/kg eldecalcitol treatment (Table 3B). In the femoral
Table 3
Bone strength.
(A) Biomechanical parameters of L3 whole vertebra compression test
Group OVX-Veh1 ELD 0.1 μg/kg OVX-Veh2 ELD 0.3 μg/kg
Peak load (N) 2444 ± 251 3088 ± 305 1666 ± 174 3069 ± 259⁎
Apparent strength (MPa) 25.53 ± 1.62 34.33 ± 3.31 20.81 ± 1.78 33.14 ± 3.03⁎
Yield load (N) 1970 ± 218 2587 ± 187 1407 ± 206 2669 ± 226⁎
Yield stress (MPa) 20.5 ± 1.2 29.1 ± 2.7 16.7 ± 2.0 29.0 ± 2.4⁎
Stiffness (N/mm) 10,184 ± 718 13,401 ± 1006⁎ 8045 ± 935 12,408 ± 1051⁎
Elastic modulus (MPa) 878 ± 87 1210 ± 142 757 ± 74 1091 ± 115⁎
Work to failure (N · mm) 1105 ± 252 1562 ± 438 730 ± 129 1247 ± 238⁎
Toughness (MPa) 1.45 ± 0.32 2.14 ± 0.56 1.15 ± 0.20 1.73 ± 0.38
(B) Biomechanical parameters of L5 vertebral core compression test
Group OVX-Veh1 ELD 0.1 μg/kg OVX-Veh2 ELD 0.3 μg/kg
Peak load (N) 227 ± 70 252 ± 94 202 ± 65 268 ± 72
Apparent strength (MPa) 10.6 ± 3.0 12.2 ± 4.9 9.6 ± 2.9 12.5 ± 3.0
Yield load (N) 185 ± 59 205 ± 67 160 ± 46 280 ± 126⁎
Yield stress (MPa) 8.7 ± 2.6 9.9 ± 3.7 7.6 ± 2.1 13.3 ± 6.1⁎
Stiffness (N/mm) 1327 ± 590 1349 ± 512 1305 ± 585 2440 ± 1505⁎
Elastic modulus (MPa) 241 ± 102 244 ± 99 268 ± 117 498 ± 299⁎
Work to failure (N · mm) 56 ± 30 77 ± 66 48 ± 32 51 ± 19
Toughness (MPa) 0.68 ± 0.33 0.95 ± 0.72 0.52 ± 0.33 0.55 ± 0.19
(C) Biomechanical parameters of femoral neck shear test
Group OVX-Veh1 ELD 0.1 μg/kg OVX-Veh2 ELD 0.3 μg/kg
Peak load (N) 1419 ± 90 1363 ± 73 1107 ± 75 1385 ± 87⁎
Stiffness (N/mm) 2574 ± 307 2093 ± 257 1376 ± 176 1637 ± 225
Work to failure (N · mm) 1312 ± 110 1228 ± 108 1206 ± 115 1436 ± 109
(D) Biomechanical parameters of femur 3-point bending test
Group OVX-Veh1 ELD 0.1 μg/kg OVX-Veh2 ELD 0.3 μg/kg
Peak load (N) 1255 ± 259 1180 ± 271 948 ± 209 1073 ± 218
Ultimate stress (MPa) 235 ± 21 244 ± 25 207 ± 21 213 ± 31
Stiffness (N/mm) 1016 ± 193 1054 ± 237 828 ± 178 917 ± 207
Elastic modulus (MPa) 9865 ± 2152 11,620 ± 1930 9965 ± 972 9710 ± 1959
Work to failure (N · mm) 3040 ± 1337 2288 ± 903 1656 ± 391 2008 ± 578
Toughness (MPa) 11.0 ± 3.4 8.8 ± 2.2 6.5 ± 1.3 7.5 ± 1.8
(E) Biomechanical parameters of cortical beam 3-point bending test
Group Humerus Tibia
OVX-Veh1 ELD 0.1 μg/kg OVX-Veh2 ELD 0.3 μg/kg
Peak load (N) 20.44 ± 2.99 21.48 ± 4.55 26.64 ± 5.79 26.63 ± 4.13
Stiffness (N/mm) 13.85 ± 2.51 15.39 ± 4.35 19.76 ± 15.08 19.09 ± 3.67
Work to failure (N · mm) 28.3 ± 8.9 24.7 ± 8.4 32.1 ± 9.7 37.5 ± 11.8
Data are presented as mean ± SD.
⁎ p ≤ 0.05 vs. OVX-Vehicle control.
121S.Y. Smith et al. / Bone 57 (2013) 116–122neck, a statistically signiﬁcant increase in peak load was observed for
the animals treated with 0.3 μg/kg eldecalcitol compared to OVX-
vehicle controls (Table 3C), with non-signiﬁcant increases in stiffness
and work to failure (Table 3C). There were no statistically signiﬁcant
differences between the eldecalcitol-treated groups and OVX-vehicle
controls for any bone strength parameters in 3-point bending at the
femur diaphysis (Table 3D) or cortical beams (Table 3E).
Discussion
In this study, as in previous studies [15,16], bone turnover markers
increased following ovariectomy (Fig. 1). Eldecalcitol treatment at 0.1
and 0.3 μg/kg for 6 months suppressed bone turnover markers and
maintained them within baseline levels (Fig. 1). Bone histomorpho-
metric analysis revealed that bone resorption parameters (ES/BS,
Oc.S/BS) and bone formation parameters (OS/BS, MS/BS, Ob.S/BS) in
lumbar vertebrae were signiﬁcantly decreased by 6 months' treat-
ment with 0.3 μg/kg eldecalcitol (Table 2A). Overall suppression of
trabecular bone remodeling (Ac.f) was over 80% compared with OVX-
vehicle controls. These results indicated that ovariectomy-induced in-
crease in bone remodelingwas suppressed by treatmentwith eldecalcitol.Because of the absence of sham-operated controls in this study, we are
unable to conclude that treatment with eldecalcitol maintains, but does
not over-suppress, normal bone remodeling throughout the treatment
period. Nevertheless, these results have shown, at least, that eldecalcitol
does not induce ‘frozen bone,’—i.e. bones with no labeled surface,—at
either of the doses tested.
Areal BMD of the lumbar spine and proximal femur as measured by
DXA, as well as vBMC of the tibia as measured by pQCT did not notably
change after ovariectomy (Figs. 2, 3). Administration of eldecalcitol
signiﬁcantly increased lumbar spine aBMD relative to OVX-vehicle
controls (Fig. 2A). In particular, 0.3 μg/kg of eldecalcitol signiﬁcantly
increased hip aBMD (Fig. 2B) and tibial diaphyseal vBMC (Fig. 3B). Con-
sistent with the aBMD results, bone strength parameters of the lumbar
spine were increased by both 0.1 and 0.3 μg/kg eldecalcitol treatment
(Table 3A), and bone strength at the femoral neck was increased at
0.3 μg/kg of eldecalcitol (Table 3C). However, no signiﬁcant improve-
ment in bone strength parameters was observed in the femoral or cor-
tical beam 3-point bending tests (Table 3D, E). These results suggest
that eldecalcitol administered for 6 months in cynomolgus monkeys is
effective mainly on the strength of trabecular bone rather than that of
cortical bone. Although the vBMC of the tibial diaphysis in animals
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eldecalcitol on the biomechanical parameters of cortical bone were
only marginal and not statistically signiﬁcant (Table 3D, E). The im-
provement in bone biomechanical parameters following treatment
with eldecalcitol may largely result from improvement of trabecular
bonemicroarchitecture rather than an increase in BMD or BMC. Further
studies are required.
In the phase III clinical trial, 0.75 μg of eldecalcitol treatment re-
duced bone turnover markers (BAP and CTX) by approximately 30%,
and increased lumbar spine aBMD by 2.9% compared with baseline
at 1 year after treatment initiation [10]. The dosage used in this
study was approximately 5 times (0.1 μg/kg) and 10 times (0.3 μg/kg)
that of the clinical dosage according to the steady-state concentration
of eldecalcitol in serum (data not shown); however, based on the in-
crease in lumbar spine aBMD and the difference in bone turnover
markers, 0.75 μg of eldecalcitol treatment in postmenopausal osteopo-
rosis patients was considered comparable to 0.1 μg of eldecalcitol treat-
ment in the ovariectomized nonhuman primates. Endogenous 1α,25-
dihydroxyvitamin D3 levels in cynomolgus monkeys (Table 1) were
approximately 3 times the levels in osteoporotic patients [10]. These
observations suggest that the response of nonhuman primates to vita-
min D compounds is much lower than that of humans.
Six months' treatment with eldecalcitol reduced serum BAP levels
and serum CTX concentration (Fig. 1). Eldecalcitol also reduced
histomorphometric bone remodeling parameters: mineralizing sur-
face, osteoid surface, and eroded surface on the trabecular bone sur-
face of lumbar vertebrae (Table 2A). These results clearly indicate
that eldecalcitol worked as an anti-resorptive agent in trabecular
bone in nonhuman primates. For cortical bone, eldecalcitol treatment
did not signiﬁcantly affect bone formation parameters on both perios-
teal and endocortical surfaces of the bone (Table 2B) although bone
formation parameters on the surface of the Haversian canals were
dose-dependently suppressed by the treatment with 0.1 μg/kg and
0.3 μg/kg eldecalcitol. It is plausible that anti-resorptive activity of
eldecalcitol may differ according to the bone site.
Major limitations in this study were the absence of sham-operated
control animals and the relatively short period of treatment. Therefore,
we could not conclude that long-term treatment with eldecalcitol
maintains material properties of bone, normal bone architecture, and
normal bone turnover in cynomolgus monkeys. However, we did ﬁnd
that treatment with eldecalcitol for 6 months had positive effects on
bone mass at the lumbar spine and proximal femur in ovariectomized
cynomolgus monkeys in vivo by slowing the rate of bone turnover
with minimal evidence of hypercalcemia. Further studies should be
required to establish the safety and efﬁcacy of eldecalcitol for the treat-
ment of osteoporosis.
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